Decentralised Clinical Trials

Uses

How it works

Benefits

Evidence quality

Other

Highlighted claims

• Decentralised clinical trials move some or all trial activities away from traditional trial sites using remote and digital methods. — Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials
• DCT adoption was not significantly associated with shorter trial duration in metabolic disease trials after adjustment. — Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials
• DCTs may be fully decentralised or partially decentralised hybrid trials. — Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials
• DCTs have been promoted as reducing participant burden, improving accessibility, increasing diversity, and potentially reducing trial time and cost. — Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials
• Sponsors may adopt DCTs for accessibility, autonomy, real-world applicability, diversity, and patient-centredness rather than only timeline reduction. — Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials